Each 0.5 mL contains: Carboprost tromethamine equivalent to Carboprost 125 mcg.
Each mL contains: Carboprost Tromethamine equivalent to Carboprost 250 mcg.
Pharmacology: Carboprost Tromethamine is a uterine stimulant and is used for the control of post partum haemorrhage (PPH). Carboprost Tromethamine when administered as an intramuscular injection arrests intractable atonic post partum haemorrhage by inducing myometrial contractions. This haemostasis produced by Carboprost Tromethamine at the site of palacentation minimizes the thirds stage blood loss and thereby reduces the maternal mortality and morbidity. Also, Carboprost Tromethamine when administered prophylactically at the time of labour because of its uterine stimulant activity it complements the physiological processes during labour, resulting in reduction of the duration of third stage and hence minimize post partum blood loss.
Carboprost Tromethamine (Endoprost) is indicated for the treatment of post partum haemorrhage especially due to uterine atony which has not responded to conventional methods of management.
Carboprost Tromethamine (Endoprost) may be used prophylactically by intramuscular injection at the birth of anterior shoulder in patients with following risks: Grand multipara; Pre-eclampsia; Rapid or prolonged labour; Placental abnormalities; Previous uterine surgery; History of PPH; History of retained placenta; Over distention of uterus.
Prophylactic treatment for the control of post partum haemorrhage:
Carboprost Tromethamine (Endoprost) at a dose equivalent to 125 mcg-250 mcg should be given intramuscularly at the delivery of the anterior shoulder of fetus.
Refractory Post Partum Haemorrhage:
Carboprost Tromethamine (Endoprost) as a dose equivalent to 250 mcg should be given by deep intramuscular injection at interval of about 90 minutes. The interval may be reduced if necessary but should not be less than 15 minutes. The total dose should not exceed 2000 mcg (8 vials of 250 mcg).
Hypersensitivity to Carboprost Tromethamine.
Acute pelvic inflammatory disease.
Patients with active cardiac, pulmonary, renal or hepatic disease.
Carboprost Tromethamine (Endoprost) should be administered cautiously in patients with a history of asthma, hypo or hypertension, cardiovascular, renal or hepatic disease, anemia, jaundice, diabetes or epilepsy.
Carboprost Tromethamine (Endoprost) is not recommended in patients having chorioamnionitis during labour as it may have an inhibitory effect on Carboprost activity.
Carboprost Tromethamine (Endoprost) should be used with caution in patients with compromised or scarred uterus.
The frequent adverse effects observed are due to its contractile effect on smooth muscle, which are transient and reversible on cessation of therapy. These include vomiting, diarrhea, hyperpyrexia and flushing. The incidences of these common side effects during high dose treatment of Carboprost Tromethamine (Endoprost) can be minimized by pretreatment or co-administration of antiemetic and antidiarrheal drugs.
Should be stored in refrigerator (2-8ºC). Do not freeze.
G02AD04 - carboprost ; Belongs to the class of prostaglandins. Used to induce abortion or augment labour and to minimize blood loss from the placental site.
Soln for inj (vial) 125 mcg/0.5 mL x 2 mL x 1's, 5's. 250 mcg/mL x 2 mL x 1's, 5's.